ZYMEWORKS INC. Operating Income
ZYMEWORKS INC. (ZYME) reported Operating Income of -$42.18 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- ZYMEWORKS INC. operating income (loss) for the quarter ending 2026-06-30 was -$42.18M.
- ZYMEWORKS INC. operating income (loss) for the quarter ending 2026-03-31 was -$47.12M.
- ZYMEWORKS INC. operating income (loss) for the quarter ending 2025-12-31 was -$44.15M.
- ZYMEWORKS INC. operating income (loss) for the quarter ending 2025-09-30 was -$22.11M.
- ZYMEWORKS INC. operating income (loss) for fiscal 2025 was -$92.55M.
- ZYMEWORKS INC. operating income (loss) for fiscal 2024 was -$137.11M.
- ZYMEWORKS INC. operating income (loss) for fiscal 2023 was -$138.05M, a 205.77% decline from fiscal 2022.
- ZYMEWORKS INC. operating income (loss) for fiscal 2022 was $130.53M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$42.18M 10-Q · filed 2026-08-06 | -$89.30M 10-Q · filed 2026-08-06 | -$133.45M derived: sum of 3 quarters · filed 2026-08-06 | -$155.56M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$47.12M 10-Q · filed 2026-05-07 | -$91.27M derived: sum of 2 quarters · filed 2026-05-07 | -$113.38M derived: sum of 3 quarters · filed 2026-05-07 | -$114.05M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$44.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$66.26M derived: sum of 2 quarters · filed 2026-03-02 | -$66.94M derived: sum of 3 quarters · filed 2026-08-06 | -$92.55M 10-K · filed 2026-03-02 |
| 2025-09-30 | -$22.11M 10-Q · filed 2025-11-06 | -$22.78M derived: sum of 2 quarters · filed 2026-08-06 | -$48.40M 10-Q · filed 2025-11-06 | -$70.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$674.00K 10-Q · filed 2026-08-06 | -$26.29M 10-Q · filed 2026-08-06 | -$48.50M derived: sum of 3 quarters · filed 2026-08-06 | -$82.71M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$25.61M 10-Q · filed 2026-05-07 | -$47.83M derived: sum of 2 quarters · filed 2026-05-07 | -$82.03M derived: sum of 3 quarters · filed 2026-05-07 | -$124.92M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$22.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$56.42M derived: sum of 2 quarters · filed 2026-03-02 | -$99.31M derived: sum of 3 quarters · filed 2026-03-02 | -$137.11M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$34.20M 10-Q · filed 2025-11-06 | -$77.09M derived: sum of 2 quarters · filed 2025-11-06 | -$114.89M 10-Q · filed 2025-11-06 | -$138.31M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | -$42.89M 10-Q · filed 2025-08-07 | -$80.69M 10-Q · filed 2025-08-07 | -$104.11M derived: sum of 3 quarters · filed 2026-03-02 | -$137.35M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$37.80M 10-Q · filed 2025-05-08 | -$61.22M derived: sum of 2 quarters · filed 2026-03-02 | -$94.46M derived: sum of 3 quarters · filed 2026-03-02 | -$148.57M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | -$23.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$56.66M derived: sum of 2 quarters · filed 2026-03-02 | -$110.77M derived: sum of 3 quarters · filed 2026-03-02 | -$138.05M 10-K · filed 2026-03-02 |
| 2023-09-30 | -$33.24M 10-Q · filed 2024-10-31 | -$87.35M derived: sum of 2 quarters · filed 2024-10-31 | -$114.63M 10-Q · filed 2024-10-31 | $204.76M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-06-30 | -$54.11M 10-Q · filed 2024-08-01 | -$81.39M 10-Q · filed 2024-08-01 | $238.00M derived: sum of 3 quarters · filed 2025-03-05 | $187.64M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-03-31 | -$27.28M 10-Q · filed 2024-05-02 | $292.11M derived: sum of 2 quarters · filed 2025-03-05 | $241.76M derived: sum of 3 quarters · filed 2025-03-05 | $175.93M derived: sum of 4 quarters · filed 2025-03-05 |
| 2022-12-31 | $319.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $269.04M derived: sum of 2 quarters · filed 2025-03-05 | $203.21M derived: sum of 3 quarters · filed 2025-03-05 | $130.53M 10-K · filed 2025-03-05 |
| 2022-09-30 | -$50.36M 10-Q · filed 2023-11-07 | -$116.18M derived: sum of 2 quarters · filed 2023-11-07 | -$188.87M 10-Q · filed 2023-11-07 | -$229.72M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | -$65.82M 10-Q · filed 2023-08-10 | -$138.51M 10-Q · filed 2023-08-10 | -$179.36M derived: sum of 3 quarters · filed 2024-03-06 | -$240.32M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | -$72.69M 10-Q · filed 2023-05-08 | -$113.53M derived: sum of 2 quarters · filed 2024-03-06 | -$174.50M derived: sum of 3 quarters · filed 2024-03-06 | |
| 2021-12-31 | -$40.85M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | -$101.81M derived: sum of 2 quarters · filed 2024-03-06 | -$215.63M 10-K · filed 2024-03-06 | |
| 2021-09-30 | -$60.96M 10-Q · filed 2022-11-08 | -$174.78M 10-Q · filed 2022-11-08 | ||
| 2020-12-31 | -$187.47M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |